Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 2,503 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,503 shares of the business’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $77,067.37. Following the sale, the chief operating officer now owns 203,783 shares of the company’s stock, valued at approximately $6,274,478.57. This represents a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Young also recently made the following trade(s):

• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total value of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total value of $281,800.00.

Akero Therapeutics Stock Down 4.3 %

Shares of AKRO stock traded down $1.32 on Thursday, hitting $29.03. The stock had a trading volume of 332,877 shares, compared to its average volume of 844,207. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $37.00. The business has a 50 day moving average price of $30.77 and a 200 day moving average price of $26.99. The company has a market cap of $2.03 billion, a PE ratio of -7.74 and a beta of -0.23. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Research analysts anticipate that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. Citigroup began coverage on Akero Therapeutics in a research note on Monday, November 18th. They set a “buy” rating and a $65.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a report on Monday, November 18th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $46.83.

Institutional Investors Weigh In On Akero Therapeutics

A number of hedge funds have recently made changes to their positions in AKRO. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after buying an additional 446 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its stake in Akero Therapeutics by 13.8% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock worth $485,000 after purchasing an additional 2,049 shares in the last quarter. Handelsbanken Fonder AB grew its position in Akero Therapeutics by 12.4% during the 3rd quarter. Handelsbanken Fonder AB now owns 20,000 shares of the company’s stock worth $574,000 after purchasing an additional 2,200 shares during the last quarter. LMR Partners LLP increased its stake in Akero Therapeutics by 17.0% during the 3rd quarter. LMR Partners LLP now owns 20,597 shares of the company’s stock valued at $591,000 after purchasing an additional 2,997 shares in the last quarter. Finally, Eastern Bank acquired a new stake in shares of Akero Therapeutics during the third quarter worth $100,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.